Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003075 · ClinicalTrials.gov registry record · Phase 3
Fenretinide in Treating Patients With Cervical Neoplasia
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
- 39
- Enrollment target
NCT00003075: Completed Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00003075 is a Phase 3 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 39 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003075, a Phase 3 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 39 participants
- Enrollment target
Study Summary
RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of fenretinide to placebo in treating patients with cervical neoplasia.
Interventions
- OTHER Placebo
- DRUG Fenretinide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1993-03-05 |
| Est. Completion | 2001-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003075
The ClinicalTrials.gov registry entry for NCT00003075 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00003075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003075 about?
NCT00003075 is a clinical study titled "Fenretinide in Treating Patients With Cervical Neoplasia". RATIONALE: Chemoprevention uses drugs to try and prevent development of cancer. Fenretinide may be effective in treating cervical neoplasia and preventing cervical cancer. PURPOSE: Randomized double-blinded phase III trial to compare the effectiveness of fenretinide to placebo in treating patients ...
What is the current status of trial NCT00003075?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 39 participants. The study started on 1993-03-05. Estimated completion is 2001-05-01.
What interventions are being tested in trial NCT00003075?
The interventions under investigation include: Placebo (OTHER), Fenretinide (DRUG).
Who is sponsoring clinical trial NCT00003075?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.